Horizon Health Call: Boosting translation of biotech research into innovative health therapies

Under the Horizon Health destination “Developing and using new tools, technologies and digital solutions for a healthy society” the HORIZON-HLTH-2025-01-TOOL-05 call is an excellent opportunity for translation of biotech research into commercially viable health therapies.

2025 Horizon Health Call: Boosting the translation of biotech research into innovative health therapies

Call summary

Deadline: 16 September 2025

Project budget: €4- €8M. Proposed EU contribution going to SMEs must be 50% or more of the total EU contribution to the project as a whole.

Call budget: €80 million.

Type of Action: Research and Innovation Actions

Applicants: At least three legal entities in different Member States or Associated Countries

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results directed towards and contributing to all the following expected outcomes:

• Healthcare providers, researchers and patients get faster access to innovative therapies.
• The European Union benefits from more clinical trials being conducted with new biotech therapeutic approaches.
• The competitiveness of small and medium-sized enterprises (SMEs) from the EU and Associated Countries within the health biotech sector is strengthened.

Scope: This topic aims to speed up the development of innovative biotechnology-based therapies by supporting the initial phases of clinical research. SMEs play a key role in the EU’s potential to innovate, with most biotechnology-derived drugs in development being progressed by SMEs and small biotech companies. However, transitioning from drug discovery and development stages to approved products requires substantial investment and sufficient resources in different areas (e.g., manufacturing, clinical trial management, regulatory affairs, etc.), with the time needed for clinical development often exceeding 10 years 205 .

Download our 2025 Horizon Europe Guide

There’s a lot to take into consideration when applying for Horizon Europe funding: budget, consortium partners, application processes, activities, and specific conditions. Our Horizon Europe Guide gives you insights on how to write a strong proposal, success criteria and maximises your chances of getting funded.

Download our free guide

This topic targets collaborative multidisciplinary consortia of SMEs, academics, clinicians and research organisations bringing together the necessary expertise to launch the clinical development of novel biotechnology-derived therapeutics. Collaboration with the relevant European research infrastructures is encouraged. This topic does not address the full clinical development needed to bring products to market but aims to support the critical transition phase from preclinical to clinical development by supporting the early clinical phases. A non-exhaustive list of biotechnology-derived therapies in scope include monoclonal antibodies, (therapeutic) vaccines, recombinant biomolecules, Advanced Therapy Medicinal Products (ATMPs), nanobased drugs, RNA therapies etc. Whole blood, blood components and other substances of human origin are not within the scope of this topic.

Proposals submitted under this topic should include all the following elements:

• A Clinical study either phase I, II or I/II depending on the appropriate stage of development.
• The proposal should convincingly demonstrate a significant economic potential of the final product(s) for the Single Market.
• A clearly defined exploitation plan, with a detailed proposed route to commercialisation, description of the intellectual property ownership and benefit for the SME(s). The plan should include an anti-shelving strategy, commercial forecasts for the product sales & revenue, and strategies for follow-up financing as well as market authorisation. The exploitation strategy should envisage a first deployment in the EU.
• Justification of the patient populations that will benefit directly from the development of the therapies. Clinical indications where potentially large patient populations could benefit will be favoured.

The maximum project duration should not exceed four years. Applicants should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.

The European Commission has published all work programmes in full. You can access the full list of EC publications for each work programme here. 

Visit the official Horizon Europe website